CA-NETAPP
1.3.2021 14:02:06 CET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, and Aston Martin Cognizant Formula One™ today announced a multi-year partnership as the world-famous car company gears up for its return to Formula One competition. After more than 60 years away, the British car brand returns to the F1™ grid, supported by NetApp, with a new edge: an innovative approach to racing utilizing the power of data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005160/en/
The partnership with NetApp reinforces Aston Martin Cognizant Formula One Team’s commitment to unlocking the very best of cloud by outfitting the team with world-class data and cloud services. Broad and ambitious in scope, the partnership will focus on maximizing performance both on and off the track.
From trackside to factory to cloud, the data used to inform Aston Martin Cognizant Formula One Team’s racing strategies will be available in real time on a global scale. With a data fabric powered by NetApp, the team will be able to extract more value from their data to better gauge car performance and address necessary refinements before, during, and after each race.
This data fabric will also help reduce operational complexities, while ensuring data compliance, security, and protection of the team’s intellectual property. By standardizing on NetApp across all platforms, the British racing team will be able to maximize resource utilization and remove inefficient data silos, enabling costly IT investments to be diverted back into car and team development.
“We are thrilled to partner with Aston Martin Cognizant Formula One as it embarks on a highly ambitious data journey in pursuit of greater speed, higher reliability and unmatched efficiency,” said James Whitemore, chief marketing officer at NetApp. “By tapping into our 28 years of data-centric innovation, we are proudly supporting the team as they push the boundaries of continuous performance improvement beyond the finish line.”
“Formula One teams have always been pioneers in analyzing data for a competitive advantage, especially when milliseconds mean the difference between pole position and starting somewhere in the middle of the pack,” said Otmar Szafnauer, chief executive officer and team principal at Aston Martin Cognizant Formula One. “The team’s partnership with NetApp, along with title partner Cognizant, represents a new stage in our journey of continuous improvement. We are excited to introduce NetApp as we strive to make everything we do faster and smarter. By empowering our brilliant team of people with NetApp’s industry-leading data solutions, we are ushering in a new era of racing where we can constantly evolve to be a faster, smarter and more exciting team.”
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
About Aston Martin Cognizant Formula One Team
After more than 60 years away from Formula One, Aston Martin returns to Grand Prix racing in 2021. With one of the most iconic emblems in the world above the garages and a team of almost 500 passionate men and women at its heart, this is a team with both a rich heritage and a fresh perspective – bringing new energy to the sport with a determination to shake up the order and compete at the sharp end.
Our mission is to use the global platform of motorsport to engage a new wave of fans – showcasing the technology and innovation which live at our core while representing the values that resonate with the changing world in which we live.
The new age of Aston Martin Cognizant Formula One Team begins here.
www.astonmartinf1.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005160/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom